Restructuring Costs

12 Months Ended

Dec. 31, 2014

Restructuring and Related Activities [Abstract]

Restructuring Costs

Restructuring Costs:

2014

Subsequent to the Par Sterile Acquisition, we eliminated approximately 25 redundant positions within Par Pharmaceutical and accrued severance and other employee-related costs for those employees affected by the workforce reduction in the first quarter of 2014.

($ amounts in thousands)

Restructuring Activities (Par Sterile)	Initial Charge		Additional Charge		Cash Payments			Non-Cash Charge Related to Inventory and/or Intangible Assets		Reversals, Reclass or Transfers		Liabilities at December 31, 2014
Severance and employee benefits to be paid in cash		$1,146		$3,527		($2,686	)		$—		$—		$1,987
Total restructuring costs line item		$1,146		$3,527		($2,686	)		$—		$—		$1,987

Due to the change in our product development strategy, we eliminated approximately 44 redundant positions within our Irvine location and accrued severance and other employee-related costs for these employees affected by the workforce reduction.

($ amounts in thousands)

Restructuring Activities (Irvine)	Initial Charge		Additional Charge		Cash Payments			Non-Cash Charge Related to Inventory and/or Intangible Assets		Reversals, Reclass or Transfers		Liabilities at December 31, 2014
Severance and employee benefits to be paid in cash		$740		$—		($127	)		$—		$—		$613
Total restructuring costs line item		$740		$—		($127	)		$—		$—		$613

2013

In January 2013, we initiated a restructuring of Par Specialty, our branded pharmaceuticals division, in anticipation of entering into a settlement agreement and corporate integrity agreement that terminated the U.S. Department of Justice’s ongoing investigation of Par Specialty’s marketing of Megace^® ES. We reduced our Par Specialty workforce by approximately 70 people, with the majority of the reductions in the sales force. The remaining Par Specialty sales force has been reorganized into a single sales team of approximately 60 professionals that focus their marketing efforts principally on Nascobal^® Nasal Spray. In connection with these actions, we incurred expenses for severance and other employee-related costs as well as the termination of certain contracts. There were no remaining liabilities at December 31, 2014 on the consolidated balance sheet.

($ amounts in thousands)

Restructuring Activities	Initial Charge		Cash Payments			Non-Cash Charge Related to Inventory and/or Intangible Assets			Reversals, Reclass or Transfers			Liabilities at December 31, 2014
Severance and employee benefits to be paid in cash		$1,413		($1,409	)		$0			($4	)		$—
Asset impairments and other	403		—			(403		)	—			—
Total restructuring costs line item		$1,816		($1,409	)		($403	)		($4	)		$—